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Abstract
The cellular and molecular mechanisms that are involved in airway hyper-responsiveness are
unclear. Current studies suggest that tumor necrosis factor (TNF)-a, a cytokine that is
produced in considerable quantities in asthmatic airways, may potentially be involved in the
development of bronchial hyper-responsiveness by directly altering the contractile properties
of the airway smooth muscle (ASM). The underlying mechanisms are not known, but
growing evidence now suggests that most of the biologic effects of TNF-a on ASM are
mediated by the p55 receptor or tumor necrosis factor receptor (TNFR)1. In addition,
activation of TNFR1 coupled to the tumor necrosis factor receptor-associated factor
(TRAF)2–nuclear factor-kB (NF-kB) pathway alters calcium homeostasis in ASM, which
appears to be a new potential mechanism underlying ASM hyper-responsiveness.
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Introduction
Asthma, which is characterized by airway inflammation,
exaggerated airway reactivity to contractile agonists, and a
decrease in b-adrenoceptor-mediated airway relaxation,
remains a common cause of pulmonary morbidity and mor-
tality. Although the mechanisms that underlie changes in
airway responsiveness are unknown, recent reports support
the notion that inflammatory mediators, which are present in
high levels in asthmatic airways, directly modulate ASM
function. Using cultured human ASM cells that retain their
physiologic responsiveness to agonists [1], investigators
have shown that TNF-a markedly stimulates the synthetic
function of ASM, defined as secretion of cytokines and
chemokines and stimulation of expression of the adhesion
molecules, intercellular adhesion molecule (ICAM)-1 and
vascular cell adhesion molecule-1 (for review [2]). In addi-
tion, new evidence shows that TNF-a also induces a hyper-
contractile phenotype by enhancing agonist-induced
calcium signals, as well as agonist-induced force generation
(for review [3]). These data represent important findings
because changes in ASM phenotype induced by cytokines
may play a role in the airway remodeling and bronchial
hyper-responsiveness that is observed in asthma. A better
understanding of the mechanisms that modulate ASM func-
tion may lead to the development of new therapeutic inter-
ventions for the treatment of asthma.
The present review examines recent studies that investi-
gated the potential mechanisms activated by TNF-a that
modulate ASM responsiveness.Respiratory Research    Vol 1 No 1 Amrani et al
Intracellular calcium regulates TNF-a a signaling
in various cell types
Growing evidence suggests that intracellular calcium plays
an important role in mediating the biologic effects of
cytokines. Many studies have shown that cytokines, by acti-
vating specific receptors coupled to a variety of signaling
pathways, generate or modulate the calcium responses
and/or alter regulatory proteins that are involved in calcium
signaling. For example, studies suggest that TNF-a gener-
ates calcium responses in different cell types such as 3T3
cells, skin fibroblasts [4,5], astroglial cells [6], U937 cell
line [7] and human neutrophils [8]. TNF-a-induced calcium
signals may be stimulated by several distinct pathways,
including an indirect emptying of intracellular calcium
stores through the generation of second messengers.
Accordingly, reports show that TNF-a can directly activate
inositol phosphate turnover in some but not all cell types,
as a result of phospholipase C stimulation [4,9,10].
Additionally, stimulation of calcium influx due to direct acti-
vation of plasma membrane-associated calcium channels
represents an alternative mechanism by which TNF-a
increases cytosolic calcium concentration [11]. Interest-
ingly, TNF-a activates crucial proteins that are involved in
maintaining calcium homeostasis. TNF-a stimulates the
expression of a calcium-binding protein, calbindin-D28K,
in neuronal cells [12], and increases activity of proteins
with calcium pumping properties in fetal pancreatic islets
[13]. The effects of TNF-a on calcium homeostasis proba-
bly mediate some cellular functions that are important in
regulating local inflammation. For example, TNF-a-induced
modulation of cytosolic calcium induces cell death in the
transformed cell line L929 [9], cell toxicity in cardiac
myocytes [14], impairment of function in neuronal cells [6],
and perturbation of insulin secretion by Langerhans’ islets
[13]. Collectively, these studies suggest that changes in
calcium homeostasis represent a new mechanism by
which TNF-a may regulate cellular responses.
TNF receptor 1 induces airway smooth muscle
cell hyper-responsiveness
Studies now show that TNF-a alters ASM contractile
function in a manner that mimics that observed in vivo in
asthmatic patients. In a sensitized guinea pig model,
inhibiting TNF-a completely abrogated the development
of bronchial hyper-responsiveness and airway inflamma-
tion [15••]. ASM exposed to TNF-a either in vitro or in
vivo become hyper-responsive to many contractile ago-
nists (for review [3]). We also found that murine tracheal
rings preincubated with TNF-a for 24 h have an
increased contractile response to carbachol (Fig. 1). The
underlying mechanism remains unclear, but our data
show that ASM cells pretreated with TNF-a also potenti-
ated calcium signals induced by a variety of contractile
agonists. These studies suggest that TNF-a is able to
‘prime’ ASM cells for a nonspecific increase in calcium
responsiveness, because TNF-a alone had no effect on
cytosolic calcium levels [16,17•].
In other studies we reported that TNF-a significantly
enhances phosphoinositide turnover in response to
bradykinin [18]. The use of agonistic antibodies or recom-
binant proteins of TNF-a that specifically activate either
TNFR1 or TNFR2 receptor led us to conclude that TNF-a
mediates most of its cellular effects by activating the
TNFR1 receptor [17•]. The effect of TNF-a on calcium
responses therefore appears to involve a modulatory
effect on G-protein-mediated signal transduction via its
TNFR1 receptor. The specific target could be at the level
of either G-protein or phospholipase C.
In parallel studies, TNF-a increased cytosolic calcium
levels induced by NaF [18], an agent that directly activates
G-protein in ASM cells, which strongly suggests that TNF-
a effects occur downstream from the receptor, possibly at
the level of the G-proteins. Consistent with this hypothesis
are the recent findings of Hotta et al [19]. Those investiga-
tors showed that TNF-a increases expression of Gq and
Figure 1
TNF-a enhances the contractile response to carbachol in murine
tracheal rings. Murine tracheal rings were harvested and placed in
culture overnight in an equal mixture of Ham F-12 and DMEM (vol/vol,
10% fetal bovine serum) in the presence or absence of TNF-a.
Cumulative concentration–response curves to carbachol were
measured on the cultured tracheal rings and compared among fresh
controls (o, n = 18), or in the presence of 10 ng/ml (n, n = 12) or 50
ng/ml TNF-a (l, n = 12), or in the absence of TNF-a (¡, n = 7) for 24
h. Isometric measurements of tracheal reactivity were calculated as
changes in milligram tensions per milligram weight (mg/mg) and
expressed as percentage of 10–5 mol/l carbachol-induced tensions.
Although TNF-a appeared to augment carbachol-induced force
generation in cultured murine tracheal rings, it is interesting to note
that carbachol-induced increases in force generation were also
increased as compared with those obtained in freshly harvested
tissues. Results are expressed as mean ± standard error of the mean.
*P < 0.05.c
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Gi proteins in human ASM cells. It remains to be defined
whether both phenomena, that is, increased receptor-
mediated calcium responses and increased smooth
muscle responsiveness, are linked.
Alteration in the receptor–G protein–phospholipase C sig-
naling pathway by TNF-a is probably not the only mecha-
nism by which TNF-a modulates contractile agonist
responses. By simultaneously measuring the intracellular
calcium levels and isometric tensions in response to acetyl-
choline, Nakatani et al [20] recently showed that brief
exposure to TNF-a for 30 min enhanced contractile
responses to acetylcholine by increasing the calcium sensi-
tivity of contractile elements in bovine tracheal smooth
muscle. Such brief exposure of cells to TNF-a probably has
little effect on protein synthesis, the other mechanism that
has been shown to mediate the effects of TNF-a on
calcium homeostasis [18]. Surprisingly, TNF-a did not
affect the calcium signals induced by acetylcholine. Similar
results were also described in guinea pig tracheal smooth
muscle, in which TNF-a also increased calcium sensitivity
[21••]. Together, these studies suggest that brief treatment
with TNF-a may modulate ASM contractile response by
directly inducing calcium sensitization of intracellular con-
tractile elements, rather than by modulating agonist-evoked
calcium mobilization induced by longer pretreatment with
TNF-a. Fig. 2 summarizes potential mechanisms by which
TNF-a modulates ASM responsiveness.
Together, these studies support the notion that TNF-a
may play a central role in modulating ASM responsiveness
by inducing both early (less than 1 h) and late (greater
than 4 h) alteration signals that modulate agonist-induced
calcium homeostasis and/or force generation.
TNF receptor 1 signaling pathways that are
activated in airway smooth muscle cells
TNF receptor-associated factor-2–nuclear factor k kB pathway
TNF-a activates at least two cell-surface receptors –
TNFR1 (55 kDa) and TNFR2 (75 kDa) – that are
expressed in most cell types (for review [22]). Both recep-
tors are expressed on cultivated human ASM cells [17•]
and on native ASM [23]. Evidence shows that the intracel-
lular signals that couple TNFR1 include an intracellular
signal protein termed ‘TNF receptor-associated death
domain’ [24]. Upon engagement of TNFR1, this intracellu-
lar signal protein acts as an adapter by recruiting the
downstream transducer TRAF2, which stimulates NF-kB
activation [24,25].
In addition to the effects of TNF-a on agonist-evoked
calcium signals, we also reported that activation of TNFR1
by TNF-a regulates the expression of functional ICAM-1
on human ASM cells [23]. Using ASM cells transfected
with an NF-kB reporter, our data also showed that TNF-a
and htr-9, an activating antibody against TNFR1, both
activated NF-kB [23,26••]. Furthermore, overexpression of
Figure 2
Potential intracellular mechanisms involved in the modulation of ASM hyper-responsiveness induced by TNF-a via TNFR1. Activation of TNFR1
coupled to the TRAF2–NF-kB pathway induces a delayed effect, in which long-term pretreatment with TNF-a enhances G-protein-coupled signal
transduction, leading to increased calcium signals to contractile agonists. Activation of TNFR1 may also be involved in a rapid effect, in which
short-term pretreatment with TNF-a enhances the calcium sensitization of intracellular contractile elements [20,21••]. IP3, inositol-1,4,5-
trisphosphate; PLC, phospholipase C.a dominant-negative TRAF2 construct, lacking the amino-
terminal RING finger, completely abrogated both TNF-a-
mediated and htr-9-mediated increases in NF-kB reporter
activity [23]. Collectively, these data suggest that TRAF2
plays a role in TNFR1-mediated NF-kB activation in ASM
cells. Interestingly, activation of NF-kB and expression of
ICAM-1 by TNF-a in ASM cells were insensitive to dexam-
ethasone pretreatment, a commonly used therapeutic
agent in the treatment of asthma [26••]. In many other
cells, however, TNF-a-induced NF-kB activation is exquis-
itely sensitive to steroids [27].
Intracellular calcium stores
In order to define the role of intracellular calcium in TNF-a
signaling, we studied the effect of thapsigargin, a specific
inhibitor of intracellular calcium pumps (ie sarco-endoplas-
mic reticulum calcium-ATPase), on gene expression. In
many cell types, thapsigargin has been shown to stimulate
calcium signals by directly emptying intracellular stores
without activating second messenger systems (for review
[28]). Evidence supports the notion that thapsigargin-sen-
sitive calcium pools are enhanced by TNF-a and are medi-
ated by TNFR1 activation (for review [3]). Interestingly,
thapsigargin-sensitive calcium stores were also found to
be those activated by contractile agonists [29]. These
data suggest that modulation of internal calcium stores
may be involved in the potentiating effect of TNF-a on
agonist-induced calcium signals.
Present evidence also shows that thapsigargin-sensitive
calcium pools modulate TNF-a-induced gene expression in
human ASM cells. Thapsigargin, in a dose-dependent
manner, inhibited about 50% of the TNF-a-induced ICAM-1
expression [23]. The calcium chelator 1,2-bis(2-aminophe-
noxy)ethane-N,N,N,N-tetraacetic acid acetoxymethyl-ester,
which clamps the cytosolic calcium concentration, also
inhibited ICAM-1 stimulated by TNF-a [23]. Surprisingly,
thapsigargin suppressed TNF-a-mediated NF-kB-depen-
dent gene transcription, an effect that was not due to
cytokine-induced IkBa degradation or NF-kB nuclear
translocation, which are crucial steps for NF-kB activation
[23]. The mechanisms by which thapsigargin modulates
gene expression remain unclear. In rat myocytes and NIH
3T3 fibroblasts, however, emptying internal calcium stores
inhibits protein synthesis by acting at the level of translation
initiation through the inactivation of the translation initiation
factor eIF2a [30,31]. Additional studies support the notion
that thapsigargin-sensitive calcium pools may modulate
gene expression in an NF-kB-dependent manner. This
hypothesis is also supported in other cell types, because a
variety of agents that alter endoplasmic reticulum function
are able to modulate NF-kB activation (for review [32•]).
Thapsigargin may also affect pathways that modulate
calcium homeostasis that are located in the nucleus that is
believed to play a central role in stimulating gene expres-
sion. Recently, Adebanjo et al [33] showed the existence of
a potential CD38/ADP ribosyl-cyclase pathway within the
nucleosome that triggers nucleoplasmic calcium release via
the production of cyclic ADP ribose. Further studies are
needed to elucidate the precise mechanism that mediates
thapsigargin inhibitory effects on gene expression.
Conclusion
Characterization of the cellular and biochemical events
that regulate ASM function will likely lead to new therapeu-
tic approaches in the management of asthma. In ASM
cells, activation of TNFR1 coupled to the TRAF2–NF-kB
pathway ‘primes’ airway myocytes to augment calcium
signals in response to thapsigargin and contractile ago-
nists, an effect that may, in part, be due to the cross-talk
between TNFR1 activation and internal calcium stores. A
better understanding of TNFR1 signaling in ASM cells
may offer new insight into the mechanisms that regulate
both airway inflammation and bronchial hyper-responsive-
ness in asthma.
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